INTERIM REPORT 1/4-30/6 2020

POSITIVE DEVELOPMENT IN CLINICAL TRIALS, FINANCIAL POSITION AND ORGANIZATIONAL READYNESS FOR MARKET LAUNCH OF INDITREAT®

2cureX pushes forward on its clinical trials within colorectal, ovarian and pancreatic cancer. Despite delays due to the COVID-19 pandemic, 2cureX still plans to launch IndiTreat® in 2020. To support our market strategy, we have established our first clinical partnership with a major Swedish hospital (Skåne University Hospital) besides entering into a distributor agreement for Portugal and Spain. The Early Access Program has confirmed the strong need and desire among clinicians to include a Functional Precision Medicine test like IndiTreat® in daily practice. 2cureX will exploit this momentum during the coming market launch. The competitive strength of 2cureX is underlined by the fact that we have received three major international grants in the present quarter.

2cureX continues to present a strong financial position with a cash position of SEK 30 million at the end of Q2. In the first week of July 2020 2cureX closed a Directed Issue transaction adding SEK 40 million to the cash balance.

(KSEK) if not stated otherwise	Q2 2020 *1/4-30/6*	Q2 2019 *1/4-30/6*	Q1-Q2 2020 *1/1-30/6*	Q1-Q2 2019 *1/1-30/6*	2019 *1/1-31/12*
Net sales	0	0	0	0	0
Other operating income	3 408	2 299	6 011	4 586	11 982
Profit before tax	-3 568	-3 122	-4 797	-5 035	-9 411
Earnings per share*	-0,25	-0,26	-0,34	-0,41	-0,68
Equity ratio**	71%	81%	71%	81%	74%
Cash and bank	30 070	34 105	30 070	34 105	33 720
Average number of shares	12 420 000	11 214 396	12 420 000	10 784 586	11 609 014
No. of shares by the end of the period	12 420 000	12 420 000	12 420 000	12 420 000	12 420 000

**Earnings per share:* *Profit for the period divided by the average number of shares.*

***Equity ratio:* *Shareholder's equity divided by total capital.*

Key events in Q2 2020:

- In April, 2cureX established a clinical **partnership with Skåne University Hospital** being our first partnership with a major Swedish hospital.

- In April, 2cureX and its clinical partner, University Medical Center Hamburg- Eppendorf, received a **grant from Federal Ministry of Education and Research (BMBF)**, Germany of 810.000 EUR, for adapting IndiTreat to guide immunotherapy in ovarian cancer.

- In April, 2cureX´s German subsidiary and Hahn-Schickard, Freiburg **received a grant from BMBF**, Germany of 1 MEUR, to support our ongoing strategy towards automation of the IndiTreat® test.

- In May, 2cureX **signed a distributor agreement with Lab52** to support commercialization of IndiTreat® in Portugal and Spain.

- In June, 2cureX established a **collaboration with Scandion Oncology A/S and Erasmus Medical Centre,** Rotterdam, in drug-resistant breast cancer patients. The project is supported by a Eurostars Grant of EUR 800.000.

- In June, 2cureX received the **third payment from the EU' Horizon** SME-Instrument Program.

Key events after the reporting period:

- In July, an **Extraordinary General Meeting** approved to change the composition of the Board of Directors and issued an authorization to increase the company's share capital.

- In July, 2cureX expanded its Board of Directors with **CEO Michael Lutz and Professor, MD, CEO Nils Brünner**.

- In July, 2cureX completed a heavily oversubscribed **Directed Issue of approximately SEK 40 million**.

FOR MORE INFORMATION PLEASE CONTACT:

Ole Thastrup CEO
Mail: ot@2curex.com
Mobile: +45 2211 5399

www.2curex.com

LETTER FROM THE CEO

Despite COVID-19 we had a positive development in the second quarter of 2020. 2curex has only to a lesser extent been affected by the pandemic and has throughout the quarter been focusing on the preparations for the upcoming launch of the IndiTreat® test in the second half of 2020.

Positive development in clinical trials

COVID-19 has led to some delays in the patient recruitment into our clinical studies. I am however happy to say that we still expect to enroll the last patient in our ongoing clinical trial in metastatic colorectal cancer during Q3 2020 and publish the results in Q1 2021. The colorectal cancer trial is an interventional trial conducted at University Hospital Vejle, DK. The drug treatments for the enrolled patients are guided by the IndiTreat® test results. Treatment outcome is evaluated eight weeks after launch of treatment by CT-scanning and associated RECIST analysis.

In addition, we are expanding the scope of our ovarian cancer study, conducted together with University Medical Center Hamburg-Eppendorf, GE and Rigshospitalet, DK, to include drug-sensitivity testing on malignant ascites. Late stage ovarian cancer patients have often accumulated a collection of fluid containing cancer cells (malignant ascites) in the abdomen. A transabdominal puncture with retrieval of ascites for IndiTreat® analysis is a minimal invasive and patient friendly procedure compared to surgery or even tissue sampling from solid tumors. We (and our hospital partners) therefore see great potential in providing this version of the IndiTreat® test to ovarian cancer patients.

Adapting to the growing demand for including IndiTreat to more cancers

During our Early Access Program (Pre-launch program), executed in the spring of 2020, we were reassured that there is a pronounced desire to include a Functional Precision Medicine test like IndiTreat® in treatment design of several cancer forms. Some hospitals also expressed a wish for more cancers to be included in the IndiTreat® target group and encouraged us to examine whether de-centralized IndiTreat® testing is possible.

Consequently, we have decided in Q2 2020 to prioritize our clinical activities in ovarian and pancreatic cancer and at the same time accelerate our development of an Immunotherapy version of IndiTreat® which is supported by a grant of EUR 1 million from BMBF.

Further, we engaged in the de-centralizing of IndiTreat® testing which includes a collaboration with Hahn-Schickard Institute in Freiburg and the Department of Microsystems Engineering (“IMTEK”) at the University of Freiburg to automate the IndiTreat® analysis platform. These collaborations are also supported by a grant of EUR 1 million from BMBF.

Additional commercial partnerships

During Q2 we have strengthened our commercial presence in Portugal and Spain by signing a distributor agreement with Lab52.

Key to our business model is to have “boots on the ground” in most European markets. This will primarily be handled through partnerships with IVD Distributors. In the coming quarters the list of such partnerships will be expanded.

At the end of last quarter, we also announced the establishment of a collaboration with Scandion Oncology (DK) and Erasmus Medical Centre (NL) to improve the outcome in therapy-resistant breast

cancer. We are very excited about this collaboration. The purpose of the project is to evaluate whether the drug candidate SCO-101 can alleviate anti-estrogen resistance and to demonstrate the usefulness of IndiTreat® in stratification of breast cancer patients during clinical trials. The project further supports our strategy to position IndiTreat in more cancer entities.

Strengthening the Board of Directors and finalizing a Directed Share Issue

In line with our strategy and preparations for the launch of IndiTreat, we have in early July expanded our Board of Directors with Michael Lutz and Nils Brünner and finalized a Directed Share Issue of SEK 40 million – please see press releases published July 3 and 6.

Michael Lutz is an experienced international biotech entrepreneur, and Nils Brünner is an oncologist with extensive experience as clinician, cancer researcher and as a biotech entrepreneur e.g. Scandion Oncology. We look forward to a close collaboration with Michael and Nils who undoubtedly will add important knowledge and experience to the company.

We are truly happy with these achievements which provides a strong support for the commercialization of IndiTreat® and the continued development and growth of 2cureX.

Robust financial position

2cureX has a strong financial position with cash of SEK 30 million at end of Q2 plus additional SEK 40 million from the Direct Issue of July 2020.

The main expenditure in Q2 2020 was, as expected, the continuous clinical validation of IndiTreat. Expenditures and loss in second quarter of 2020 is in line with plans and expectations.

One of the highlights of the quarter, has been our ability to attract public grants supporting our clinical and commercial activities. Not only do two grants from BMBF provide a total of more than EUR 2 million for our immunotherapy and automation strategy, they also endorse networking and attractive partnership collaboration. The strategic partnership within breast cancer is supported by a Eurostars grant and is another good example of a collaboration project with significant clinical and commercial perspectives.

Other operating income in the second quarter of 2020 is 3 408 KSEK which reflects the effort 2cureX has put into the ongoing projects that are supported by public grants.

COVID-19

The COVID-19 pandemic has continued into Q2 of 2020 with devastating global consequences. To ensure the safety of our staff and partners, 2cureX adapted our business activities in Copenhagen and Hamburg to this new reality in the beginning of March. In Q3 we still expect to “work from home” if possible and to conduct most of our internal and external meetings digitally. In our laboratories, our staff have worked in shifts and thereby been able to accommodate all patient testing coming from our partner hospitals.

However, the pandemic has influenced 2cureX´s clinical trials in Q2 with minor delays in patient recruitment. Likewise, our distributors were unable to schedule visits to hospital. From June, the situation improved as hospitals began opening up for normal external collaboration.

I wish to thank 2cureX´s employees, partners, and patients for their essential contribution to 2cureX´s journey towards improving cancer patient outcome with the help of individualizing treatment.

2CUREX IN BRIEF

2cureX is a Medtech company that has developed the IndiTreat® test for Individualizing the treatment of cancer patients. 2cureX strives to establish IndiTreat as a global standard for Functional Precision Medicine.

2cureX was founded in 2006 as a spin-out from the Carlsberg Research Centre in Copenhagen, with the vision of improving treatment efficiency for cancer patients.

From its inception, 2cureX has been closely connected to major cancer hospitals in the Nordic countries, Germany and the UK. 2cureX has been in direct contact with patients and physicians from day one, in order to better understand the clinical course, optimal treatment and care of cancer patients.

After an intensive build-up phase including clinical testing facility and partnership establishment in 2019, 2cureX is preparing to commercialize IndiTreat in the second half of 2020.

IndiTreat® predicts the best treatment for each patient

The key product of 2cureX is the IndiTreat test which allows the physician to identify the most efficient medical treatment for a particular cancer patient.

At the same time, the test reveals drugs to which the patient is resistant. This is almost equally important to save time, cost and avoid side effects of ineffective therapy. IndiTreat is patent protected in major markets and has received CE-IVD certification which allows commercialization in Europe.

Clinical validation in colorectal, ovarian, and pancreatic cancer

Clinical validation studies are being conducted with renowned cancer hospitals in Denmark, Germany, United Kingdom and Sweden. These studies will continuously strengthen the validity of using IndiTreat® for treatment guidance.



2cureX has CE-IVD marking of the IndiTreat® test for colorectal cancer (CRC) and plans to introduce it into the European market in the second half of 2020.

Dates for market introduction of IndiTreat® for ovarian and pancreatic cancer has not yet been set.

European setup collaborating worldwide

2cureX has a strong network of partners in Europe and is planning to commercialize the IndiTreat test in the European market in the second half of 2020. The total available market in Europe for the IndiTreat test in the three cancers where 2cureX currently is operating, is estimated to 12 billion SEK. A market introduction in the US and Asian markets will follow later.

2cureX has office and laboratory facilities in Copenhagen and in Hamburg. In both places we are in direct interaction with major cancer centres. 2cureX has in the present quarter initiated an automation project that will allow IndiTreat® testing to be conducted outside 2cureX's own test analysis sites. This will open for a broader market penetration, and additional business models.

DEVELOPMENT DURING THE FIRST HALF YEAR AND THE SECOND QUARTER OF 2020, IN FIGURES

Numbers within parentheses refer to the corresponding period in the preceding year. For additional information about 2cureX's financial position and development, please refer to the Company's website (www.2cureX.com).

Net sales and operating income

Net sales during the first half of 2020 amounted to 0 KSEK (0 KSEK) and for the second quarter of 2020 net sales amounted to 0 KSEK (0 KSEK). Other operating income during the first half of 2020 amounted to 6,011 KSEK (4,586 KSEK) and for the second quarter Other operating income amounted to 3,408 KSEK (2,299 KSEK).

Financial development

The result during the first half of 2020 amounted to -4,236 KSEK (-4,400 KSEK) and for the second quarter of 2020 the result amounted to -3,087 KSEK (-2,863 KSEK). The result for the period has been impacted by the conduct of clinical trials initiated to validate the IndiTreat® technology. A significant part of the clinical operations is funded by an EU grant called MicroCaT, recognized as Other operating income in the income statement.

Liquidity

The Group's cash and cash equivalents amounted to 30,070 KSEK (34,105 KSEK) as of June 30, 2020. Cash flow during the first half of 2020 amounted to -3,908 KSEK (13,892 KSEK) and for the second quarter of 2020 cash flow amounted to 1,547 KSEK (16,895 KSEK). Cash flow from operating activities during the first half of 2020 amounted to -3,765 KSEK (-7,953 KSEK) and in the second quarter of 2020 cash flow from operating activities amounted to 1,620 KSEK (-4,950 KSEK). The monthly burn rate is approximately 1.7 MSEK, which is in line with the expectations.

Solidity

The Group's equity ratio as of June 30, 2020 amounted to 71 % (81 %).

The share

There is one class of shares in 2cureX AB (publ). The Company's share is listed on Nasdaq First North Growth Market under the ticker "2CUREX". As of June 30, 2020, the number of shares amounted to 12,420,000 (12,420,000). The average number of shares during the second quarter of 2020 amounted to 12,420,000 (11,214,396).

Employee stock options

The Annual General Meeting on 28 May 2018 resolved to establish a Series 2018/2020 and a Series 2018/2021 warrant program for the Group's employees and key personnel. The employee warrants, totaling 360,000 warrants, carry the right to subscribe for newly issued shares in 2cureX AB in the period

28 May 2020 to 28 September 2020 and in the period 1 April 2021 to 28 September 2021, respectively. Each subscription warrant entitles the holder to subscribe for 1 share, at a subscription price of SEK 8.86 per share. Upon full exercise of the issued warrants, the share capital would increase by 36,000 SEK. The employee warrants will be subject to the usual conversion terms in connection with new share issues etc. The Group's result during the first half of 2020 has been impacted by costs in the amount of 500 KSEK (355 KSEK) in the form of personnel costs.

Policies for the preparation of the interim financial report

2cureX AB applies the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3) in the preparation of its financial reports.

Auditors' review

This interim report has not been reviewed by the Company's auditors.

Financial calendar

The Company prepares and publishes a financial report at the end of each quarter.
Upcoming reports are planned to be released as follows:

- **Interim report Q3, 2020 26/11-2020**
- **Year-end report, 2020 28/2-2021**

2CUREX PARTICIPATES AT ESMO VIRTUAL CONGRESS 2020

19 – 21 September 2020
(Exhibition 14 September to 18 October 2020)

WE ARE LOOKING FORWARD TO LAUNCH INDITREAT TO THE WORLD'S LEADING ONCOLOGY PROFESSIONALS.

Stay tuned – we will be posting news from the Congress on an ongoing basis on www.2curex.com/ESMO2020

With more than 25,000 members, ESMO represents oncology professionalsfrom over 160 countries worldwide, ESMO is the society of reference for oncology education and information.

For more information:
https://www.esmo.org/

DELIVERY OF INTERIM REPORT

Landskrona, august 27, 2020
2cureX AB

BOARD OF DIRECTORS

Povl-André Bendz
Chairman of the Board

Jørgen Drejer
Board

Camilla Huse Bondesson
Board

Nils Brünner
Board

Michael Lutz
Board

Ole Thastrup
Board and CEO

Certified Adviser
Redeye AB
Phone: **+46 8 121 576 90**
E-mail: **certifiedadviser@redeye.se**

FINANCIAL OVERVIEW

SUMMARY OF INCOME STATEMENT – THE GROUP

(KSEK)	Q2 2020 *1/4-30/6*	Q2 2019 *1/4-30/6*	Q1-Q2 2020 *1/1-30/6*	Q1-Q2 2019 *1/1-30/6*	2019 *1/1-31/12*
Operating income					
Net sales	0	0	0	0	0
Other operating income	3 408	2 299	6 011	4 586	11 982
Total operating income	**3 408**	**2 299**	**6 011**	**4 586**	**11 982**
Operating expenses					
Other external expenses	-2 219	-2 160	-4 373	-3 608	-9 376
Personnel costs	-3 375	-3 010	-6 305	-5 507	-10 919
Depreciation of tangible fixed assets	-94	-110	-185	-211	-436
Total operating expenses	**-5 688**	**-5 280**	**-10 863**	**-9 326**	**-20 731**
Operating profit	**-2 280**	**-2 981**	**-4 852**	**-4 740**	**-8 749**
Financial posts	-1 288	-141	55	-295	-662
Profit before tax	**-3 568**	**-3 122**	**-4 797**	**-5 035**	**-9 411**
Tax ***1)***	481	259	561	635	1 478
The result of the period	**-3 087**	**-2 863**	**-4 236**	**-4 400**	**-7 933**
Earnings per share (SEK)	-0,25	-0,26	-0,34	-0,41	-0,68
Average number of shares	12 420 000	11 214 396	12 420 000	10 784 586	11 609 014
No. of shares at the end of the period	12 420 000	12 420 000	12 420 000	12 420 000	12 420 000

1) *This post refers to tax relief in subsidiaries regarding R&D work.*

SUMMARY OF BALANCE SHEET – THE GROUP

(KSEK)	Q1-Q2 2020 *1/1-30/6*	Q1-Q2 2019 *1/1-30/6*	2019 *1/1-31/12*
Assets			
Fixed assets			
Tangible fixed assets	981	1 225	1 015
Total fixed assets	**981**	**1 225**	**1 015**
Current assets			
Receivables	3 387	3 520	3 106
Cash and bank balances	30 070	34 105	33 720
Total current assets	**33 457**	**37 625**	**36 826**
Total assets	**34 438**	**38 850**	**37 841**
Equity and liabilities			
Equity			
Share capital	1 242	1 242	1 242
Other contributed capital	38 023	38 023	38 023
Other equity	-10 625	-3 220	-3 256
The result of the period	-4 236	-4 400	-7 933
Total equity	**24 404**	**31 645**	**28 076**
Current liabilities			
Short-term liabilities ***2)***	10 034	7 205	9 765
Total short-term liabilities	**10 034**	**7 205**	**9 765**
Total equity and liabilities	**34 438**	**38 850**	**37 841**

2) *This post includes prepaid contributions from the EU amounting to 7 120 KSEK (5 150 KSEK).*

SUMMARY OF CASH FLOW – THE GROUP

(KSEK)	Q2 2020 *1/4-30/6*	Q2 2019 *1/4-30/6*	Q1-Q2 2020 *1/1-30/6*	Q1-Q2 2019 *1/1-30/6*	2019 *1/1-31/12*
Cash flow from operating activities	1 620	-4 950	-3 765	-7 953	-7 864
Cash flow from investment activities	-73	0	-143	0	-20
Cash flow from financing activities	0	21 845	0	21 845	21 845
Cash flow for the period	**1 547**	**16 895**	**-3 908**	**13 892**	**13 961**
Cash and cash equivalents at the beginning of the period	30 018	17 167	33 720	20 063	20 063
Exchange rate difference in cash and cash equivalents	-1 495	43	258	150	-304
Cash and cash equivalents at the end of the period	**30 070**	**34 105**	**30 070**	**34 105**	**33 720**

CHANGE OF EQUITY – THE GROUP

1/1-2019 – 31/12-2019

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period *(1/1-2019)*	**1 035**	**16 385**	**3 465**	**-7 264**	**13 621**
Outline of previous year's results			-7 264	7 264	0
Rights issue	207	24 529			24 736
Issue costs		-2 891			-2 891
Allocation of staff warrants			316		316
Translation difference			227		227
The result of the period				-7 933	-7 933
At the end of the period *(31/12-2019)*	**1 242**	**38 023**	**-3 256**	**-7 933**	**28 076**

1/1-2020 – 30/6-2020

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period *(1/1-2020)*	**1 242**	**38 023**	**-3 256**	**-7 933**	**28 076**
Outline of previous year's results			-7 933	7 933	0
Allocation of staff warrants			494		494
Translation difference			70		70
The result of the period				-4 236	-4 236
At the end of the period *(30/6-2020)*	**1 242**	**38 023**	**-10 625**	**-4 236**	**24 404**

SUMMARY OF INCOME STATEMENT – PARENT COMPANY

(KSEK)	Q2 2020 *1/4-30/6*	Q2 2019 *1/4-30/6*	Q1-Q2 2020 *1/1-30/6*	Q1-Q2 2019 *1/1-30/6*	2019 *1/1-31/12*
Operating income					
Net sales	0	0	0	0	0
Total operating income	**0**	**0**	**0**	**0**	**0**
Operating expenses					
Other external expenses	-680	-670	-961	-971	-1 694
Staff costs	0	-36	0	-36	-265
Total operating expenses	**-680**	**-706**	**-961**	**-1 007**	**-1 959**
Operating profit	**-680**	**-706**	**-961**	**-1 007**	**-1 959**
Financial posts	-211	-333	-23	-333	42
Profit before tax	**-891**	**-1 039**	**-984**	**-1 340**	**-1 917**
Tax	0	0	0	0	0
The result of the period	**-891**	**-1 039**	**-984**	**-1 340**	**-1 917**

SUMMARY OF BALANCE SHEET – PARENT COMPANY

(KSEK)	Q1-Q2 2020 *1/1-30/6*	Q1-Q2 2019 *1/1-30/6*	2019 *1/1-31/12*
Assets			
Fixed assets			
Financial assets	27 848	5 000	27 376
Total fixed assets	**27 848**	**5 000**	**27 376**
Current assets			
Receivables	175	913	298
Cash and bank balances	1 628	30 762	2 534
Total current assets	**1 803**	**31 675**	**2 832**
Total assets	**29 651**	**36 675**	**30 208**
Equity and liabilities			
Equity			
Share capital	1 242	1 242	1 242
Other contributed capital	42 223	42 223	42 223
Other equity	-13 069	-11 629	-11 646
The result of the period	-984	-1 340	-1 917
Total equity	**29 412**	**30 496**	**29 902**
Current liabilities			
Current liabilities	239	6 179	306
Total short-term liabilities	**239**	**6 179**	**306**
Total equity and liabilities	**29 651**	**36 675**	**30 208**

CASH FLOW STATEMENT IN SUMMARY – PARENT COMPANY

(KSEK)	Q2 2020 *1/4-30/6*	Q2 2019 *1/4-30/6*	Q1-Q2 2020 *1/1-30/6*	Q1-Q2 2019 *1/1-30/6*	2019 *1/1-31/12*
Cash flow from operating activities	-436	-4 963	-906	-5 377	-1 206
Cash flow from investment activities	0	0	0	0	-32 399
Cash flow from financing activities	0	21 845	0	21 845	21 845
Cash flow for the period	**-436**	**16 882**	**-906**	**16 468**	**-11 760**
Cash and cash equivalents at the beginning of the period	2 064	13 880	2 534	14 294	14 294
Cash and cash equivalents at the end of the period	**1 628**	**30 762**	**1 628**	**30 762**	**2 534**

CHANGE OF EQUITY – PARENT COMPANY

1/1-2019 – 31/12-2019

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period *(1/1-2019)*	**1 035**	**20 585**	**-516**	**-11 446**	**9 658**
Outline of previous year's results			-11 446	11 446	0
Rights issue	207	24 529			24 736
Issue costs		-2 891			-2 891
Allocation of staff warrants			316		316
The result of the period				-1 917	-1 917
At the end of the period *(31/12-2019)*	**1 242**	**42 223**	**-11 646**	**-1 917**	**29 902**

1/1-2020 – 30/6-2020

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period *(1/1-2020)*	**1 242**	**42 223**	**-11 646**	**-1 917**	**29 902**
Outline of previous year's results			-1 917	1 917	0
Allocation of staff warrants			494		494
The result of the period				-984	-984
At the end of the period *(30/6-2020)*	**1 242**	**42 223**	**-13 069**	**-984**	**29 412**

2CUREX AB (publ)

Corporate registration number
559128-0077

Fruebjergvej 3
DK-2100 Copenhagen
Denmark
Phone: **+45 2211 5399**
E-mail: **info@2curex.com**

– because cancer patients are individuals